All News
Filter News
Found 2,297 articles
-
Beam Therapeutics Founded by Gene Editing Pioneers to Create Precision Genetic Medicines with Base Editing
5/14/2018
Beam Therapeutics announced today that it is launching to develop precision genetic medicines
-
Moderna Therapeutics and Merck expanded their 2016 collaboration deal to develop and commercialize personalized messenger RNA (mRNA) cancer vaccines. The new deal will include mRNA cancer vaccines that share antigens, including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine.
-
Moderna and Merck Expand mRNA Cancer Vaccines Collaboration
5/3/2018
Moderna Therapeutics and Merck announced an expansion of their 2016 collaboration to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines to now include shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine.
-
Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study
4/26/2018
1Q18 Total Revenues of $930.9 Million, a 7 Percent Increase Over 1Q17 and a 7 Percent Volume Increase
-
Vertex Reports First-Quarter 2018 Financial Results
4/26/2018
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the first quarter ended March 31, 2018.
-
Billions of dollars are being invested in Boston-based life science companies.
-
Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment of $50 Million
3/14/2018
Company's Proprietary Gene Traffic Control™ product platform provides a new way to think about treating disease.
-
Giuseppe Ciaramella, formerly chief scientific officer of Moderna Therapeutics’ Valera unit, has left for an unidentified stealth-mode biotech startup.
-
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
-
If you had a crystal ball, you probably would have invested in Berkshire Hathaway in 1964, or Apple in the 1980s.
-
One can only hope that Moderna Therapeutics can live up to the hype, both scientifically and financially.
-
Flagship Pioneering Catalyzes Growth With New Leadership Appointments
2/1/2018
Flagship Pioneering today announcing the appointment of two new partners: Rob Rosiello, executive partner and chief operating officer, and Jason Pontin, senior partner and chief editor.
-
Avacta and OncoSec to Collaborate on Innovative Gene Delivery of Therapeutic Affimers
1/22/2018
The research programme will evaluate the benefits of delivering Affimer protein genes directly into tumors using the OncoSec technology with the long-term aim of developing gene delivered Affimer immunotherapies.
-
Moderna unleashed a torrent of updates yesterday.
-
Adimab Provides Year-End Update on 2017 Partnership Activities
1/8/2018
Adimab today announced that in 2017 it entered into agreements with seven new companies.
-
Perosphere Pharmaceuticals Appoints Robert S. Langer, Sc.D. to its Board of Directors
1/8/2018
Perosphere Pharmaceuticals Inc. announced today that it has appointed Robert S. Langer, Sc.D., founding Chairman of Perosphere's Scientific Advisory Board and Institute Professor, MIT, to its Board of Directors.
-
The Series A round was entirely funded by founding investor Apple Tree Partners.
-
Dr. Mendlein will be responsible for corporate strategy, product advancement and strategy, partnering and product protection.
-
Kaleido Biosciences Announces Appointment of Wendy Arnold as Senior Vice President, Human Resources
1/3/2018
Ms. Arnold, who brings more than 20 years of experience in human resources to Kaleido, will report directly to chief executive officer and chair, Michael Bonney.
-
Moderna to Provide Corporate and Pipeline Updates and Outline Strategic Priorities at 2018 J.P. Morgan Healthcare Conference
1/2/2018
Mr. Bancel’s presentation will take place on Monday, January 8, 2018 at 2:30 p.m. PT in Elizabethan Room C/D at The Westin St. Francis Hotel in San Francisco.